iRhythm links with Verily to help diagnose 'silent' afib cases

E-Tattoo takes the hassle out of heart monitoring
For access to Verily’s health data analytics technologies, iRhythm will pay $5 million upfront and up to $12.75 million in milestone payments. (Pixabay)

Wearable electrocardiogram maker iRhythm Technologies has begun working with Verily Life Sciences to develop ways to better screen, diagnose and manage patients living with so-called “silent” atrial fibrillation.

IRhythm estimates that, of the patients who suffer a stroke due to afib, about 1 in 5 were previously unaware of their heart rhythm disorder. The company says more than 10 million people in the U.S. may be at high risk for the condition, with about one-third going undiagnosed.

Afib is also associated with higher stroke risks and more severe cases when they do occur as well as other risk factors such as high blood pressure, diabetes and sleep apnea. To develop a kind of early warning system, iRhythm and Verily aim to build solutions to help identify asymptomatic, high-risk patients in underserved populations before a major cardiac event happens.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Verily’s patient-centric approach to disease management and advanced hardware capabilities will prove critical in providing patients and providers with the tools needed to increase the efficiency of heart healthcare,” Kevin King, iRhythm president and CEO, said in a statement.

RELATED: Novartis, Otsuka, Pfizer, Sanofi join Verily's Project Baseline

For access to Verily’s health data analytics technologies, iRhythm will pay Verily $5 million upfront, and the devicemaker has committed to as much as $12.75 million in development and regulatory milestone payments. Meanwhile, iRhythm will supply its 14-day wearable biosensor devices as well as its experience in artificial intelligence-based arrhythmia diagnosis.

RELATED: iRhythm ECG patch study shows fewer atrial fibrillation hospitalizations, more outpatient visits

“With the high prevalence of cardiovascular-related health issues, we have an opportunity to not only improve how we diagnose, manage and monitor conditions like atrial fibrillation, but also develop patient-centric solutions that could ultimately prevent serious cardiac events,” said Verily’s chief medical and scientific officer Jessica Mega.

Suggested Articles

The facility, to be based in the new life sciences center One Discovery Square, is expected to open before the end of this year.

The FDA announced plans to join two collaborative communities focused on real-world evidence and ophthalmic imaging.

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.